Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinar...
Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting
About this item
Full title
Author / Creator
Publisher
London, England: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Scope and Contents
Contents
The use of targeted therapeutics known as poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the management of ovarian cancer is currently transforming clinical practice. The PARP inhibitor rucaparib is indicated in the UK, European Union and the United States for use in the treatment and maintenance settings for patients with relap...
Alternative Titles
Full title
Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_3f63c5cc85b74c81bc129307a9b5a654
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3f63c5cc85b74c81bc129307a9b5a654
Other Identifiers
ISSN
1758-8359,1758-8340
E-ISSN
1758-8359
DOI
10.1177/1758835920921980
